Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06658886

Comparison of the Efficacy of Ultrasound-Guided Corticosteroid Injection and Paraffin Therapy in Carpal Tunnel Syndrome

The aim of this study is to compare the efficacy of paraffin therapy, a physical therapy modality, and ultrasound-guided corticosteroid injection in the treatment of carpal tunnel syndrome, the most common entrapment neuropathy. By doing so, the study will evaluate the effectiveness and feasibility of these two alternative, low-side-effect treatments for managing this frequently encountered condition.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Beylikdüzü State Hospital

Istanbul, Beylikdüzü, 34147, Turkey (Türkiye)

Location status: Recruiting

Location contact

Büşra Şirin

CONTACT

[email protected]

02124443322

About this study

A total of 46 patients, aged 18-65, diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies, will be included in the study.Pain levels will be assessed using the Visual Analog Scale (VAS), and functional impairment will be measured with the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ). Electrophysiological evaluations will be performed by a neurology specialist at the 1st and 3rd month follow-ups outside of working hours and without being billed to the Social Security Institution (SGK). VAS, BCTQ scores, and electrophysiological parameters will be evaluated at baseline, and at the 4th and 12th-week follow-ups post-treatment. Electrophysiological measurements will include median nerve distal motor latency (MMNDL), median nerve distal sensory latency (MNSDL), sensory nerve conduction velocity (SNCV), compound muscle action potential (CMAP), and sensory nerve action potential (SNAP) amplitudes.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18-65.
  • Diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies.
  • Received either ultrasound-guided corticosteroid injection or paraffin therapy.
  • Symptoms persisting for at least 3 months.

Exclusion criteria

  • Diagnosis of other conditions causing neuropathic symptoms (e.g., polyneuropathy, brachial plexopathy, thoracic outlet syndrome).
  • History of previous injection or surgery for carpal tunnel syndrome.

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. Visual Analog Scale (VAS):

    Time frame: 0 day, 4th week and 12th week

    The VAS will be used to measure pain intensity. Patients will mark their pain level on a 10 cm scale, where 0 represents "no pain" and 10 represents the "worst imaginable pain." This will be evaluated at baseline, and at the 4th and 12th weeks post-treatment.

  2. Boston Carpal Tunnel Syndrome Questionnaire Symptom Severity Scale (BCTQ-SSS)

    Time frame: 0 day, 4th week and 12th week

    The SSS assesses the severity of carpal tunnel symptoms such as pain, tingling, and numbness. The total score for this scale ranges from a minimum of 11 to a maximum of 55. A lower score indicates mild or no symptoms, while a higher score suggests more severe symptoms. As the score increases, the severity of symptoms worsens, with a score closer to 55 reflecting a significantly greater impact on daily life.

  3. Boston Carpal Tunnel Syndrome Questionnaire Functional Status Scale (BCTQ-FSS)

    Time frame: 0 day, 4th week and 12th week

    The SSS assesses the severity of carpal tunnel symptoms such as pain, tingling, and numbness. The total score for this scale ranges from a minimum of 11 to a maximum of 55. A lower score indicates mild or no symptoms, while a higher score suggests more severe symptoms. As the score increases, the severity of symptoms worsens, with a score closer to 55 reflecting a significantly greater impact on daily life.

Secondary outcomes

  1. Median nerve distal motor latency

    Time frame: 0 day, 4th week and 12th week

    It is a finding from electrophysiological evaluation

  2. Median nerve distal sensory latency

    Time frame: 0 day, 4th week and 12th week

    It is a finding from electrophysiological evaluation

  3. Sensory nerve conduction velocity

    Time frame: 0 day, 4th week and 12th week

    It is a finding from electrophysiological evaluation

  4. Motor nerve conduction velocity

    Time frame: 0 day, 4th week and 12th week

    It is a finding from electrophysiological evaluation

  5. Sensory nerve action potential amplitude

    Time frame: 0 day, 4th week and 12th week

    It is a finding from electrophysiological evaluation

  6. Motor nerve action potential amplitude

    Time frame: 0 day, 4th week and 12th week

    It is a finding from electrophysiological evaluation

Study contacts

Contact information is provided by the study sponsor or research team.

Büşra Şirin Ahısha

CONTACT

[email protected]

02124443322

Büşra Şirin Ahısha, MD

CONTACT

[email protected]

(0212) 856 27 40

Sponsors and collaborators

Lead sponsor

Beylikduzu State Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 26, 2024
Registry last updated
Dec 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.